Business
Ruvidar Effective in the Treatment of Herpes
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus ...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Ruvidar Effective in the Treatment of HerpesRuvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus the standard of care treatments Acyclovir and Abreva in a preclinical animal model.Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (\"Theralase®\" or the \"Company\"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that RuvidarTM has demonstrated a higher efficacy in the treatment of Herpes Simplex Virus, Type 1 (\"HSV-1\") versus standard of care treatments Acyclovir (1%) and Abreva in a preclinical animal model.Herpes Simplex Virus (\"HSV\"), known as herpes, is a very common infection that can cause painful blisters or ulcers on the skin of an individual. It primarily spreads by skin-to-skin contact, while it is treatable, it is not curable.1There are two main types of HSV:1Type 1 (\"HSV-1\") generally spreads by oral contact and causes infections in or around the mouth, vermilion, upper or lower lip region (oral herpes or cold sores). It can also cause genital herpes. A majority of adults are infected with HSV-1.Type 2 (\"HSV-2\") spreads by sexual contact and causes herpes in the genital region of an individual.An estimated 3.8 billion people under the age of 50 (64%) globally have HSV-1, the main cause of oral herpes. An estimated 520 million people aged 15 to 49 (13%) globally have HSV-2, the main cause of genital herpes.1The global HSV treatment market size was estimated at $USD 2.8 billion in 2024 and is expected to balloon to $USD 4.7 billion by 2033.2 The market growth can be attributed to the growing concerns over HSV infection, including, oral and genital herpes. Moreover, the infection is highly contagious, spreading via saliva, vaginal secretion or semen and is acquired unknowingly. These factors highlight the increasing need for treatment throughout the projected period.3North America accounted for the largest market share of 37.1% in 2024, which can be attributed to higher consumption of branded herpes drugs, escalating healthcare expenditure, increasing launch of generi...